{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:48:31Z","timestamp":1774579711923,"version":"3.50.1"},"reference-count":23,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Institutes of Health Research","award":["PJT-183802-2022"],"award-info":[{"award-number":["PJT-183802-2022"]}]},{"name":"Canadian Institutes of Health Research","award":["41698"],"award-info":[{"award-number":["41698"]}]},{"name":"Canadian Institutes of Health Research","award":["2024-2027-PSOv2d-69502"],"award-info":[{"award-number":["2024-2027-PSOv2d-69502"]}]},{"name":"Canadian Foundation for Innovation (John R. Evans Leaders Fund\u2014Funding for infrastructure program)","award":["PJT-183802-2022"],"award-info":[{"award-number":["PJT-183802-2022"]}]},{"name":"Canadian Foundation for Innovation (John R. Evans Leaders Fund\u2014Funding for infrastructure program)","award":["41698"],"award-info":[{"award-number":["41698"]}]},{"name":"Canadian Foundation for Innovation (John R. Evans Leaders Fund\u2014Funding for infrastructure program)","award":["2024-2027-PSOv2d-69502"],"award-info":[{"award-number":["2024-2027-PSOv2d-69502"]}]},{"name":"Minist\u00e8re de l\u2019\u00c9conomie de l\u2019Innovation et de l\u2019\u00c9nergie (MEIE)","award":["PJT-183802-2022"],"award-info":[{"award-number":["PJT-183802-2022"]}]},{"name":"Minist\u00e8re de l\u2019\u00c9conomie de l\u2019Innovation et de l\u2019\u00c9nergie (MEIE)","award":["41698"],"award-info":[{"award-number":["41698"]}]},{"name":"Minist\u00e8re de l\u2019\u00c9conomie de l\u2019Innovation et de l\u2019\u00c9nergie (MEIE)","award":["2024-2027-PSOv2d-69502"],"award-info":[{"award-number":["2024-2027-PSOv2d-69502"]}]},{"name":"Neolys Pharma","award":["PJT-183802-2022"],"award-info":[{"award-number":["PJT-183802-2022"]}]},{"name":"Neolys Pharma","award":["41698"],"award-info":[{"award-number":["41698"]}]},{"name":"Neolys Pharma","award":["2024-2027-PSOv2d-69502"],"award-info":[{"award-number":["2024-2027-PSOv2d-69502"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Aminosteroid derivative RM-581 stands out as an anticancer agent, supported by positive in vitro and in vivo studies on resistant cancers of the breast, prostate, and pancreas. A synthetic route has already been developed to obtain aminosteroid RM-581 in small quantities (scale of milligrams to a few grams). However, this route has significant limitations in view of its transposition to scaling up to larger quantities to support late preclinical and clinical trials. Among the problems are the use of toxic reagents, the moderate overall yield, and the need for multiple purifications through chromatographic columns. The development of a new synthetic route has therefore been explored. Starting from commercially available estrone, 2,4-dibromo-estrone was rapidly formed, followed by the regioselective introduction of a nitro group at the C2 position and by the methylation of phenol at the C3 position. The 4-bromo-2-nitro-3-O-methylestrone was then reduced to 2-amino-3-O-methylestrone and the primary amine was used to form the piperazine ring. Once the cyclization step was carried out, the last two steps were identical to the first synthetic route previously reported, i.e., introducing an ethynyl group at the C-17\u03b1 position and then adding the quinoline-proline side chain with an N-acylation, assisted by a peptide coupling reagent. Importantly, no purification by chromatography was necessary during the whole sequence of reactions and only a final silica gel filtration, followed by recrystallization, led to RM-581 at a very high level of purity. The structure was also fully characterized by 2D NMR analysis.<\/jats:p>","DOI":"10.3390\/molecules30112441","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T03:57:18Z","timestamp":1748923038000},"page":"2441","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a Multigram Synthetic Route to RM-581, an Orally Active Aminosteroid Derivative Against Several Types of Cancers"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-1653","authenticated-orcid":false,"given":"Ren\u00e9","family":"Maltais","sequence":"first","affiliation":[{"name":"Laboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Qu\u00e9bec Research Center-Universit\u00e9 Laval, Qu\u00e9bec, QC G1V 4G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doriane","family":"de Sainte Maresville","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Qu\u00e9bec Research Center-Universit\u00e9 Laval, Qu\u00e9bec, QC G1V 4G2, Canada"},{"name":"Department of Molecular Medicine, Faculty of Medicine, Universit\u00e9 Laval, Qu\u00e9bec, QC G1V 0A6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Desrosiers","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Qu\u00e9bec Research Center-Universit\u00e9 Laval, Qu\u00e9bec, QC G1V 4G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Poirier","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Qu\u00e9bec Research Center-Universit\u00e9 Laval, Qu\u00e9bec, QC G1V 4G2, Canada"},{"name":"Department of Molecular Medicine, Faculty of Medicine, Universit\u00e9 Laval, Qu\u00e9bec, QC G1V 0A6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Poirier, D., Roy, J., Maltais, R., Weidmann, C., and Audet-Walsh, \u00c9. (2023). An aminosteroid derivative shows higher in vitro and in vivo potencies than gold standard drugs in androgen-dependent prostate cancer models. Cancers, 15.","DOI":"10.3390\/cancers15113033"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Burguin, A., Roy, J., Ouellette, G., Maltais, R., Bherer, J., Diorio, C., Poirier, D., and Durocher, F. (2023). Aminosteroid RM-581 decreases cell proliferation of all breast cancer molecular subtypes, alone and in combination with breast cancer treatments. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134241"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Maltais, R., Roy, J., Perreault, M., Sato, S., L\u00e9vesque, J.C., and Poirier, D. (2021). Induction of endoplasmic reticulum stress-mediated apoptosis by aminosteroid RM-581 efficiently blocks the growth of PC-3 cancer cells and tumors resistant or not to docetaxel. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011181"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10637-018-0643-4","article-title":"Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model","volume":"37","author":"Perreault","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer Statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","first-page":"3","article-title":"Five-year cancer survival by stage at diagnosis in Canada","volume":"34","author":"Ellison","year":"2023","journal-title":"Health Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kenmogne, L.C., Ayan, D., Roy, J., Maltais, R., and Poirier, D. (2015). The aminosteroid derivative RM-133 shows in vitro and in vivo antitumor activity in human ovarian and pancreatic cancers. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144890"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Dembitsky, V.M. (2023). Biological activity and structural diversity of steroids containing aromatic rings, phosphate groups, or halogen atoms. Molecules, 28.","DOI":"10.3390\/molecules28145549"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1039\/c001262a","article-title":"Steroids: Partial synthesis in medicinal chemistry","volume":"27","author":"Hanson","year":"2010","journal-title":"Nat. Prod. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jsbmb.2013.05.011","article-title":"Current status on development of steroids as anticancer agents","volume":"137","author":"Gupta","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Brito, V., Alves, G., Almeida, P., and Silvestre, S. (2021). Highlights on steroidal arylidene derivatives as a source of pharmacologically active compounds: A review. Molecules, 26.","DOI":"10.3390\/molecules26072032"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-022-00389-8","article-title":"Targeting lipa independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/OP.24.00279","article-title":"Novel therapies for pancreatic cancer","volume":"21","author":"Chung","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/OP-25-00037","article-title":"Challenges in the management of advanced prostate cancer","volume":"21","author":"Ozay","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Xiong, N., Wu, H., and Yu, Z. (2024). Advancements and challenges in triple-negative breast cancer: A comprehensive review of therapeutic and diagnostic strategies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1405491"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cmdc.201600482","article-title":"Design of a mestranol 2-N-piperazino-substituted derivative showing potent and selective in\u2005vitro and in vivo activities in MCF-7 breast cancer models","volume":"12","author":"Perreault","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0039-128X(83)90033-8","article-title":"Novel and regiospecific synthesis of 2-amino estrogens via zincke nitration","volume":"41","author":"Numazawa","year":"1983","journal-title":"Steroids"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.steroids.2014.01.008","article-title":"Chemical synthesis, NMR analysis and evaluation on a cancer xenograft model (HL-60) of the aminosteroid derivative RM-133","volume":"82","author":"Maltais","year":"2014","journal-title":"Steroids"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9989","DOI":"10.1016\/j.tet.2009.09.114","article-title":"Propylphosphonic anhydride (t3p\u00ae): An efficient reagent for the one-pot synthesis of 1,2,4-oxadiazoles, 1,3,4-oxadiazoles, and 1,3,4-thiadiazoles","volume":"65","author":"Augustine","year":"2009","journal-title":"Tetrahedron"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/psc.1204","article-title":"Comu: A third generation of uronium-type coupling reagents","volume":"16","author":"Albericio","year":"2010","journal-title":"J. Pept. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.1002\/chem.200900615","article-title":"Comu: A safer and more effective replacement for benzotriazole-based uronium coupling reagents","volume":"15","author":"Prohens","year":"2009","journal-title":"Chem. Eur. J."},{"key":"ref_23","unstructured":"Labrie, F., Provencher, L., and Gauthier, S. (2004). Topical, Antiandrogenic Steroids. (WO 2004\/089971 A1)."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/11\/2441\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:23Z","timestamp":1760031983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/11\/2441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["molecules30112441"],"URL":"https:\/\/doi.org\/10.3390\/molecules30112441","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}